DNA methylation inhibitors: Retrospective and perspective view.
| Autor: | Uddin MG; Department of Pharmaceutical & Administrative Sciences, School of Pharmacy, University of Charleston, Charleston, WV, United States., Fandy TE; Department of Pharmaceutical & Administrative Sciences, School of Pharmacy, University of Charleston, Charleston, WV, United States. Electronic address: tamerfandy@ucwv.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Advances in cancer research [Adv Cancer Res] 2021; Vol. 152, pp. 205-223. Date of Electronic Publication: 2021 May 04. |
| DOI: | 10.1016/bs.acr.2021.03.007 |
| Abstrakt: | DNA methylation is an epigenetic modification that contributes to essential biological processes such as retrotransposon silencing, cell differentiation, genomic imprinting and X-chromosome inactivation. DNA methylation generates a stable epigenetic mark associated with silencing of gene expression. Aberrant DNA methylation is associated with the development of different tumor types. Reversing DNA methylation is a rational strategy to restore gene re-expression and induce cell differentiation in cancer. DNA hypomethylating agents is a class of drugs that demonstrated efficacy in different tumors. In this chapter, the classification of DNA hypomethylating agents, their pharmacodynamics and their potential drawbacks will be discussed. (Copyright © 2021 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|